NDUFB9 Antikörper (C-Term)
Kurzübersicht für NDUFB9 Antikörper (C-Term) (ABIN500208)
Target
Alle NDUFB9 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- C-Term
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human, mouse, rat
-
Aufreinigung
- Peptide affinity chromatography
-
Immunogen
- LYRM3 antibody was raised against a 17 amino acid peptide near the carboxy terminus of human LYRM3.
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
ELISA. Western blot: 1 - 2 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store the antibody (in aliquots) at -20 °C.
-
-
- NDUFB9 (NADH Dehydrogenase (Ubiquinone) 1 beta Subcomplex, 9, 22kDa (NDUFB9))
-
Andere Bezeichnung
- NDUFB9
-
Hintergrund
- LYRM3, also known as NADH dehydrogenase (ubiquinone) 1 beta subcomplex 9 (NDUFB9), is a ubiquitously expressed LYR-motif containing protein. It has been suggested to be a candidate gene for the branchio-oto-renal (BOR) syndrome, which is characterized by branchial and renal abnormalities and heredity deafness disorders. Other than its LYR-motif, LYRM3 appears to have no functional or structural relationship to either LYRM1 or LYRM2.Synonyms: Complex I-B22, LYR motif-containing protein 3, LYRM3, NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9, NADH-ubiquinone oxidoreductase B22, UQOR22
-
Gen-ID
- 4715
-
UniProt
- Q9Y6M9
-
Pathways
- Sensory Perception of Sound, SARS-CoV-2 Protein Interaktom
Target
-